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ABSTRACT
Introduction: Genotyping circulating tumor DNA (ctDNA)
is a promising noninvasive clinical tool to identify the EGFR
T790M resistance mutation in patients with advanced
NSCLC with resistance to EGFR inhibitors. To facilitate
standardization and clinical adoption of ctDNA testing
across Canada, we developed a 2-phase multicenter study to
standardize T790M mutation detection using plasma ctDNA
testing.
Methods: In phase 1, commercial reference standards were
distributed to participating clinical laboratories, to use their
existing platforms for mutation detection. Baseline performance characteristics were established using known and
blinded engineered plasma samples spiked with predetermined concentrations of T790M, L858R, and exon 19
deletion variants. In phase II, peripheral blood collected
from local patients with known EGFR activating mutations
and progressing on treatment were assayed for the presence of EGFR variants and concordance with a clinically
validated test at the reference laboratory.
Results: All laboratories in phase 1 detected the variants at
0.5 % and 5.0 % allele frequencies, with no false positives.
In phase 2, the concordance with the reference laboratory
for detection of both the primary and resistance mutation
was high, with next-generation sequencing and droplet
digital polymerase chain reaction exhibiting the best overall
concordance. Data also suggested that the ability to detect
mutations at clinically relevant limits of detection is
generally not platform-speciﬁc, but rather impacted by
laboratory-speciﬁc practices.
Conclusions: Discrepancies among sending laboratories
using the same assay suggest that laboratory-speciﬁc
practices may impact performance. In addition, a negative
or inconclusive ctDNA test should be followed by tumor
testing when possible.
 2021 The Authors. Published by Elsevier Inc. on behalf of
the International Association for the Study of Lung Cancer.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Non–small cell lung cancer; Plasma ctDNA
testing; Liquid biopsy; EGFR T790M variant

Introduction
Approximately 75 % of patients with NSCLC have
advanced disease (stage III and IV) at diagnosis.1,2 In
addition, the intrinsic aggressive behavior of lung cancer,
as illustrated by a death rate of 5 % to 7 % monthly after
initial diagnosis, emphasizes the necessity of rapid access to diagnosis and treatment for the management of
patients.3
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Patients with NSCLC harboring certain variants in the
EGFR gene are eligible for treatment with EGFR tyrosine
kinase inhibitors (TKIs) as ﬁrst-line systemic therapy.
Certain variants that occur in the tyrosine kinase domain
of EGFR, such as deletions in exon 19 and the point
mutation L858R, activate the kinase activity by a ligandindependent mechanism, leading to increased cell survival, proliferation, invasion, and metastasis. Treatment
with TKIs results in dramatic antitumor activity in a
subset of patients with NSCLC with these sensitizing
variants. Patients whose tumors initially respond to
EGFR TKIs inevitably reveal disease progression, typically within a year of starting treatment.4 The most
common mechanism of acquired resistance is the
acquisition of the T790M variant in the EGFR kinase
domain, which occurs in approximately 60 % of tumors
resistant to ﬁrst-generation and second-generation EGFR
TKIs. This mutation sterically hinders the binding of
ﬁrst- and second-generation TKIs to the adenosine
triphosphate (ATP) binding site while the afﬁnity of
EGFR for ATP is increased. Thus, the downstream
signaling is not inhibited and disease progression occurs.4,5 Selective and efﬁcient third-generation TKIs have
been developed as a means of overcoming this limitation.
These compounds selectively target activating EGFR
mutations and the T790M resistance mutation through
the formation of a covalent bond to the C797 residue in
the ATP-binding site of mutant EGFR.6–8
In patients with advanced NSCLC with EGFR T790M,
variants can be detected in tumor tissue or cell-free
circulating tumor DNA (ctDNA) extracted from
plasma.9–11 Current testing recommendations for EGFR
T790M detection include identiﬁcation of the variant in
cell-free DNA (cfDNA) of patients exhibiting clinical
progression, owing to challenges such as tumor inaccessibility, tumor heterogeneity,12 and patient
morbidity13 to obtain tumor tissue. Depending on the
platform used, the sensitivity and speciﬁcity of EGFRT790M detection from ctDNA vary from 50 % to 80 %
and 90 % to 100 %, respectively, when compared with
tumor biopsy,14,15 so subsequent testing of the tumor
specimen is recommended if the plasma result is negative.16,17 Diverse plasma ctDNA technologies in both
commercial and academic laboratories are in routine or
emerging use. However, routine liquid biopsy testing in
Canada is still in the early steps of implementation.18 In
addition to being less invasive, advantages of ctDNA
testing include faster processing compared with using
tumor tissue, and the inclusion of genetic material from
multiple sites, which might reﬂect tumor heterogeneity
more adequately.19
Tumor testing for targetable genetic alterations in
NSCLC is standard-of-care in most hospitals in Canada.
But although ctDNA testing for the T790M variant has an
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established role in the clinical management of patients
with NSCLC, technical challenges have limited the availability of this testing modality. Challenges include the
paucity of positive cases to serve as controls in validation cohorts, and the multiplicity of available assays.
Despite the availability of the required molecular platforms in many hospitals, there is the need to assess the
metrics of the assays for this testing modality during
validation. To facilitate standardization and clinical
adoption of ctDNA testing across Canada, a multicenter
RING study to explore the development and validation of
EGFR-T790M variant detection using plasma ctDNA
testing was undertaken. We compared various methodologies in this analytical and clinical validation study to
evaluate plasma T790M testing.

Materials and Methods
Experimental Design
This study was divided into an analytical validation
phase (phase 1a and 1b); and a clinical validation phase
(phase 2). The aim of phase 1 was analytical validation of
the platforms being evaluated by the participating laboratories, which included next-generation sequencing
(NGS) (Illumina TruSight Tumor 15 [TST15], Illumina;
ThermoFisher Oncomine Lung cfDNA assay, Thermo
Fisher Scientiﬁc), the QX200 AutoDG droplet digital polymerase chain reaction (ddPCR) system (Bio-Rad systems), the Entrogen ctEGFR Mutation Detection kit, Cobas
EGFR Mutation Test version 2 (EntroGen), and UltraSEEKTM Lung Panel for the MassARRAY System (Agena
Bioscience). Phase 2 encompassed the clinical validation
by a subset of the participating sites from phase 1. A total
of nine Canadian institutions participated in phase 1 and
seven continued onto phase 2. The platforms, assays, and
cfDNA extraction kits used by each of the sites are provided in Table 1. Reference laboratory testing was provided by the Division of Clinical Laboratory Genetics,
University Health Network for all phases, as the liquid
biopsy assay had already been clinically validated in this
laboratory.20 The reference laboratory method was
ddPCR using the Bio-Rad Assay with custom integrated
DNA Technologies primers and probes.

Phase 1: Platform Assessment and Analytical
Validation
In phase 1a, laboratories were provided with commercial plasma samples (Horizon Discovery, Cambridge,
United Kingdom), which consisted of human genomic
DNA derived from cancer cell lines fragmented to 160
base pairs, with levels of 0.05 %, 0.5 %, and 5 % of EGFR
variants (L858R, T790M, E746-A750del, T790M/L858R
mixture), and one 0 % mutant (100 % wild-type) control. These were processed according to technical
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guidelines provided by the manufacturer. When possible,
the ctDNA was isolated using locally established protocols at each site (Table 1). In phase 1b, the laboratories
were provided with ﬁve commercially derived reference
standards, though they were blinded to the identity of
the variants and corresponding mutant allele frequencies. These samples were processed similarly to
those in phase 1a. The primary objective of phase 1 was
to enable the laboratories to choose the platform that
best ﬁts their need, and to determine the quality metrics
and run parameters for each platform to obtain clinically
relevant analytical sensitivity and speciﬁcity.

Phase 2: Clinical Validation
Patients were enrolled from participating sites in
accordance with each site’s standard process for identifying patients eligible for testing of EGFR T790M. Institutional ethics approval was obtained for all participating
sites. Patients’ consent was taken before the initial blood
draw. Each participating site collected whole blood samples in DNA Streck tubes (10 mL each), with two tubes
being retained for in-house ctDNA extraction and analysis,
and two tubes sent to the reference laboratory for parallel
clinical testing and reporting. The methods for Cobas
(Roche Diagnostics, Indianapolis, IN), ddPCR, Entrogen
detection kit, and NGS (Illumina TST15, ThermoFisher
Oncomine Lung) assays of plasma circulating T790M
variant are described in the Appendix. Laboratory 1
collected the validation data from all sites and collated it
with the clinical molecular reports provided by the
reference site (Fig. 1).
The sensitizing variants (exon 19 deletions and
L858R) were used as a marker for the presence of ctDNA
in the samples. The results from each center were
compared with those reported by the reference laboratory at the conclusion of the study to determine
concordance with the reference center ﬁndings. Results
were reported as follows: (1) “detected” when the
T790M variant was identiﬁed; (2) “undetected” if the
sensitizing variant was detected but T790M was not, or
if the sensitizing mutation was not tested; (3) and
“inconclusive” if both the T790M and sensitizing variant
were undetectable.
In addition, patient recruitment by laboratory 1
included peripheral blood samples and a corresponding
tumor biopsy or a cytology specimen. Because of
different institutional research ethics board policies in
the other six sites participating in phase 2, a subsequent
tumor or cytology specimen was obtained only after a
negative or inconclusive result by the reference laboratory, and if a further biopsy was possible, which was
aligned with the standard-of-care at the time in these
centers.
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Table 1. Testing Sites, Platforms Used, and Study Phase Participation
cfDNA Extraction Kit
Used

Laboratory #

Platform Used

Assays

Phase 1

Phase 2

1

Droplet digital PCR

X

X

QIAamp circulating
nucleic acid kit

2

NGS (S5)

X

X

3

NGS

X

X

4

Real-time PCR (Cobas 4800)

X

X

5

Real-time PCR

X

X

6

Real-time PCR

X

X

7

Real-time PCR (Cobas 4800)

X

X

8

Real-time PCR (Cobas 4800)

9

Mass array

Bio-Rad EGFR assay and IDT
(Integrated DNA
Techonologies) designed
primers and probes
ThermoFisher Oncomine
Lung cfDNA assay
IlluminaTruSight Tumor 15 TST15 panel
Cobas EGFR mutation test
v2
Entrogen ctEGFR mutation
detection kit
Entrogen ctEGFR mutation
detection kit
Cobas EGFR Mutation test
v2
Cobas EGFR mutation test
v2
UltraSEEK lung panel

Reference
laboratory

Droplet digital PCR

QIAamp circulating
nucleic acid kit
QIAamp circulating
nucleic acid kit
Cobas cfDNA sample
preparation kit
Nucleosnap kit for plasma
DNA
QIAamp circulating
nucleic acid kit
Cobas cfDNA sample
preparation kit
Cobas cfDNA sample
preparation kit
QIAamp circulating
nucleic acid kit
QIAamp circulating
nucleic acid kit

Bio-Rad EGFR assay and IDT
designed primers and
probes

X
X
X (1b only)

X

#, number; cfDNA, cell-free DNA; IDT, integrated DNA Technologies; NGS, next-generation sequencing; PCR, polymerase chain reaction.

Figure 1. Phase 2 specimen collection, analysis, and results from transmission workﬂow. In phase 2, peripheral blood was
collected in Streck tubes from patients with previously identiﬁed sensitizing EGFR mutations and who were exhibiting signs of
clinical progression. Two Streck tubes were used for in-house validation of the platforms being evaluated by the participating
labs, whereas another two tubes were shipped to the reference laboratory for routine clinical testing. A RING study number
was also generated for each patient in the validating laboratory and sent along with the test requisition and specimens to the
reference laboratory. For the duration of the validation, each patient specimen in the validating laboratory only had the RING
study number for identiﬁcation, which accompanied the subsequent results of the validation to laboratory 1 for data
collation. On completion of testing by the reference laboratory, clinical reports were issued to the referring oncologist. At
the same time, results were also sent to laboratory 1 (with only the corresponding RING study number) for collation with
results from the validating laboratory. #, number; ID, identiﬁcation document.
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Table 2. Phase 1a Results
Phase 1a
Samples

Mutation

Laboratory
1 (ddPCR)

Laboratory 2 (NGS ThermoFisher
Oncomine)

Laboratory 3 (NGS Illumina TST15)

None detected
T790M
T790M
L858R
L858R
L858R
None detected
DE746-A750
DE746-A750
L858R
L858RþT790M
L858RþT790M
None detected
Laboratory 6 (Entrogen
ctEGFR Mutation
Detection kit)
None detected
T790M
T790M
L858R
L585R
L5858R
None detected
DE746-A750
DE746-A750
L858RþT790M
L858RþT790M
L858RþT790M
None detected

None detected
T790M
T790M
L858R
L858R
L858R
None detected
DE746-A750
DE746-A750
T790M
L858RþT790M
L858RþT790M
None detected
Laboratory 7 (Entrogen
ctEGFR Mutation
Detection kit)
None detected
T790M
T790M
None detected
L858R
L858R
None detected
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected

None detected
T790M
T790M
None detected
L858R
L858R
None detected
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected
Laboratory 8 (Cobas
EGFR Mutation Test
v2)
T790M
T790M
T790M
None detected
L858R
DE746-A750þL858R
DE746-A750
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected

Sample 1
Sample 2
Sample 3
Sample 4
Sample 5
Sample 6
Sample 7
Sample 8
Sample 9
Sample 10
Sample 11
Sample 12
Sample 13
Phase 1a
Samples

EGFR T790M
EGFR T790M
EGFR T790M
EGFR L858R
EGFR L858R
EGFR L858R
EGFR DE746-A750
EGFR DE746-A750
EGFR DE746-A750
EGFR T790M/L858R
EGFR T790M/L858R
EGFR T790M/L858R
EGFR Wild-type
Mutation

0.05
0.50
5
0.05
0.50
5
0.05
0.50
5
0.05
0.50
5
0
Mutant Allelic
Frequency, %

Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample
Sample

EGFR T790M
EGFR T790M
EGFR T790M
EGFR L858R
EGFR L858R
EGFR L858R
EGFR DE746-A750
EGFR DE746-A750
EGFR DE746-A750
EGFR T790M/L858R
EGFR T790M/L858R
EGFR T790M/L858R
EGFR Wild-type

0.05
0.50
5
0.05
0.50
5
0.05
0.50
5
0.05
0.50
5
0

1
2
3
4
5
6
7
8
9
10
11
12
13

ctEGFR, circulating tumor EGFR; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; TST15, TruSight Tumor 15.

Laboratory 4 (Cobas
EGFR Mutation Test
v2)

Laboratory 5 (Cobas
EGFR Mutation Test
v2)

None detected
T790M
T790M
None detected
L858R
DE746-A750þL858R
DE746-A750
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected
Laboratory 9 (UltraSEEK
Lung Panel)

None detected
T790M
T790M
None detected
L858R
DE746-A750þL858R
DE746-A750
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected

None detected
T790M
T790M
None detected
L858R
L858R
None detected
DE746-A750
DE746-A750
None detected
L858RþT790M
L858RþT790M
None detected

Detection of EGFR T790M Mutation Using ctDNA

Mutant Allelic
Frequency, %

5
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Results
Analytical Validation With Commercial Controls
(Phase 1a and 1b)
The results and details for the analytical validation
using the commercial controls (Horizon Discovery) are
summarized in Tables 2 and 3. In phase 1a, the variants
and allele fractions in each of the 13 samples were disclosed to the laboratories. These were used to determine
the limit of detection (LOD) and to evaluate falsepositive and false-negative rates for three variants: the
sensitizing DE746-A750 and L858R variants, and the
resistance T790M variant.
All three sites validating the Cobas assay (Roche Diagnostics) (laboratories 4, 7, and 8) were able to detect
the T790M variant at 0.50 % and 5 %, respectively,
though only laboratory 8 was able to detect the variant
at 0.05 % in sample 1 (Table 2). The L858R variant at
allele frequencies of 0.5 % and 5.0 % were detected by
all three labs, though none were able to detect it at
0.05 %. Interestingly, all three laboratories using the
Cobas platform reported detecting the DE746-A750
variant in sample 6, which was known to harbor only the
L858R variant at 5 %. Because none of the other platforms detected the DE746-A750 variant in this sample,
and personal communication with the manufacturer of
the controls conﬁrmed that only the L858R variant was
present, the DE746-A750 variant was presumed to be a
false-positive call. After these results, the centers using
the Cobas modiﬁed the sensitivity parameters for this
speciﬁc variant. For the remaining controls, the Cobas
detected the DE746-A750 single variant and
T790MþL858R compound variants at allele frequencies
of 5 % and 0.5 %, but not at 0.05 %.
Of the two sites validating the Entrogen kit, both sites
were able to detect the T790M, L858R, and DE746-A750
single variants and compound T790MþL858R variants
at 5 % and 0.5 %. One site was also able to detect the
L858R single variant and compound T790MþL858R
variants at 0.05 % allele frequency. Both the NGS platforms (Illumina TST15 and ThermoFisher Oncomine
lung cfDNA panels) performed comparably, being able to
detect the single T790M, L858R, DE746-A750, and
compound L858RþT790M variants at 0.5 % and 5 %.
The UltraSEEKTM mass array platform was able to
detect the single and compound variants at 0.5 % and
5.0 %, but not at 0.05 %. The droplet digital PCR platform was able to detect the single T790M and DE746A750 at 0.5 % and 5 % allele frequencies, whereas
L858R (single and compound with T790M) was also
detected at 0.05 %. No variants were detected in the
100 % wild-type (0 % mutant) control (sample 2016-10)
by any of the platforms. Collectively for phase 1a, the
0.05 % control specimens were detected as positive only
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for certain variants and by some platforms. Inconsistencies were observed among similar platforms
for the same variant at this low allele frequency.
In phase 1b, ﬁve blinded controls samples were
assayed. The results obtained are detailed in Table 3.
Brieﬂy, all platforms were able to detect the T790M
variant, either alone or as a compound with L858R at
0.5 % and 5 % allele frequencies. Similar to phase 1a, no
variants were detected in the EGFR wild-type by any of
the platforms. On the basis of the capability for all the
platforms to consistently identify the tested EGFR variants at 0.5 %, the LOD for all assays were set to 0.5 % by
the local validating labs, before proceeding to the clinical
validation in phase 2. This LOD was also in line with the
detection threshold of the ddPCR platform used by the
reference laboratory (0.5 %).

Clinical Validation (Phase 2)
Concordance of ctDNA Results With Reference Center. Seven of the nine sites went on to enroll patients for
phase 2 of the study. Collectively, 156 patients from the
seven sites consented to participate in the RING study. Of
these, 16 samples failed quality control metrics and were
therefore not processed as part of the clinical validation.
In total, 140 samples were included in phase 2. Table 4
details the EGFR T790M positivity rate per center. To
analyze the concordance among the results reported by
the reference and participating centers, all undetectable
and inconclusive results were considered as negative
results. Of the 140 patients whose plasma was processed
for testing, the reference laboratory identiﬁed an EGFR
T790M variant in 32 samples (22.9 %). Overall, the
concordance rate of the results reported by the participating laboratories with that of the reference laboratory
was high (97.9 %), with only three discordant results
collectively (Table 5), coming from participating laboratories using either the real-time PCR-based Entrogen
or Cobas assay (Roche Diagnostics). In two cases, the
reference laboratory called a T790M variant, which was
not detected by the participating laboratory; in the other,
the participating laboratory called a T790M variant that
was not detected by the reference laboratory. In addition, of the laboratories that did not detect a T790M
variant, the sensitizing EGFR variant (L858R or exon 19
deletions) was detected in only 27 % of these cases in
which the primary variant was tested for.
Because some centers used the same assay approach
(e.g., Cobas, Entrogen, and Amplicon-based NGS), data were
pooled by platform type to assess performance (Table 6). A
concordance rate of 100 % with the reference laboratory
was observed for the ddPCR platform (laboratory 1), and the
amplicon-based NGS panels (laboratories 2 and 3). A lower
concordance rate was observed for the Roche Cobas

Detection of EGFR T790M Mutation Using ctDNA

T790M
T790M
L858RþT790M
L858RþT790M
None detected

T790M
T790M
L858RþT790M
L858RþT790M
None detected
Reference Center

0.50
5
0.50
5
0
1
2
3
4
5
Sample
Sample
Sample
Sample
Sample

ctEGFR, circulating tumor EGFR; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; TST15, TruSight Tumor 15.

T790M
T790M
L858RþT790M
L858RþT790M
None detected
Laboratory 6 (Entrogen
ctEGFR Mutation
Detection kit)
T790M
T790M
L858RþT790M
L858RþT790M
None detected
EGFR T790M
EGFR T790M
EGFR T790M/L858R
EGFR T790M/L858R
EGFR Wild-type
Mutation
0.50
5
0.50
5
0
Variant Allelic
Frequency, %
Sample 1
Sample 2
Sample 3
Sample 4
Sample 5
Phase 1b
Samples

EGFR T790M
EGFR T790M
EGFR T790M/L858R
EGFR T790M/L858R
EGFR Wild-type

T790M
T790M
L858RþT790M
L858RþT790M
None detected
Laboratory 8 (Cobas
EGFR Mutation
Test v2)
T790M
T790M
L858RþT790M
L858RþT790M
None detected
T790M
T790M
L858RþT790M
L858RþT790M
None detected
Laboratory 7 (Entrogen
ctEGFR Mutation
Detection kit)
T790M
T790M
L858RþT790M
L858RþT790M
None detected

Laboratory 1 (ddPCR)
Mutation

7

(laboratories 4 and 7) and Entrogen assay (laboratories 5
and 6) at (95.8 %) and (89.5 %), respectively.

T790M
T790M
L858RþT790M
L858RþT790M
None detected
Laboratory 9
(UltraSEEK Lung
Panel)
T790M
T790M
L858RþT790M
L858RþT790M
None detected

Laboratory 3 (NGS
- Illumina TST15)
Laboratory 2 (NGS ThermoFisher
Oncomine)
Variant Allelic
Frequency. %
Phase 1b
Samples

Table 3. Phase 1b Results

Laboratory 4
(Cobas EGFR
Mutation Test v2)

Laboratory 5
(Cobas EGFR
Mutation Test v2)
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Comparison of ctDNA Results With Tumor Biopsy. Of
the 52 patients enrolled by laboratory 1, a total of 39
had results from both ctDNA and tumor testing. Of these,
13 were T790M positive by both testing modalities, 10
samples were positive (for T790M) by tissue and
negative by liquid, and 14 samples were negative for
T790M by both tissue and ctDNA testing. No sample was
negative by tissue and positive by liquid. These results
were used to calculate the concordance with the reference laboratory. For the remaining phase 2 participating
laboratories (laboratories 2–7), a tumor biopsy was
obtained only when the ctDNA analysis yielded a negative or inconclusive result and when the patient was
amenable for further tumor biopsy. The concordance
between tissue and liquid biopsy testing for each laboratory is provided in Supplementary Table 1. Collectively, 25 of the 69 samples (36.2 %) with negative
liquid biopsy results subsequently tested positive by
tissue testing. Of note, the liquid biopsy result from the
reference laboratory was used to assess the
concordance.
Serial ctDNA Testing. In a small number of patients
from laboratory 1, second (n ¼ 11) and third (n ¼ 2)
liquid biopsies were tested after inconclusive results
with the initial blood draw and when patients could not
undergo subsequent tissue biopsies. Of these 13 patients, three (23.1 %) had a positive T790M result after
a second (n ¼ 2) or a third (n ¼ 1) blood draw. The
interval of time between the additional sample ranged
between 13 and 329 days (mean ¼ 106 d) and was 69
and 137 days in positive patients.

Discussion
Plasma ctDNA represents a promising alternative to
tissue biopsy for the assessment of tumor mutational
status while avoiding challenges such as tumor inaccessibility, tumor heterogeneity, and patient comorbidities. It can also serve as a personalized biomarker to
monitor minimal residual disease and predict response
to therapy. Despite these obvious beneﬁts and clinical
utility, ctDNA analysis has not yet been translated into
routine molecular diagnostics in Canada. This, in part,
may be because of the unknown dynamics of tumor
shedding and inherent technical challenges of assessing
potentially low levels of ctDNA, and the lack of
consensus with respect to preanalytical and analytical
procedures.
Here, we present a multicenter collaboration in
which we leveraged platforms already being used by
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Table 4. Phase 2 EGFR-T790M Positivity Rate Per Center
Local Laboratory #

# Cases

# Positive Cases
(Local Laboratory)

# Positives Cases
(Reference Laboratory)

a

Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Total

52
10
35
8
12
7
16
140

13
2
8
3
5
0
0
31

13
2
8
3
4
1
1
32

25.0
20.0
22.9
37.5
33.3
14.3
6.3
22.9

1
2
3
4
5
6
7

(ddPCR)
(NGS – Oncomine Lung cfDNA)
(NGS – Illumina TST15)
(Cobas)
(Entrogen)
(Entrogen)
(Cobas)

% Positive Cases

a

Percent positive cases were based on cases detected by reference laboratory.
#, number; cfDNA, cell-free DNA; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; TST15, TruSight Tumor 15.

participating laboratories for molecular proﬁling to
facilitate the adoption and implementation of ctDNA
testing in routine molecular testing. Our ﬁndings with
both commercially available ctDNA reference material
harboring EGFR variants and clinical specimens revealed
that laboratories could consistently detect a 0.5 %
variant allelic frequency.
As evidenced from the results, all NGS systems tested
were able to consistently detect the T790M variants in
plasma for samples that were positive from the reference
laboratory. In addition to the excellent sensitivity and
speciﬁcity, NGS allows a broad survey of multiple clinically
important targets in more patients at one time compared
with single target assays, which is an important consideration as the number of clinically relevant genes and targets
in NSCLC continues to grow. The drawback, however, with
NGS platforms is that the increased sensitivity requires
increasing the coverage or read depth for each sample
necessitating fewer samples per sequencing run. Inevitably, this translates to increased costs.
In the nonsequencing space, the ddPCR platform
evaluated by laboratory 1 also displayed excellent
sensitivity and speciﬁcity. The reliability of ddPCR in the
detection and quantiﬁcation of rare mutant alleles has
been reported elsewhere, and this approach has been
proposed to have a higher sensitivity compared with

NGS.21 In addition to lower-cost reagents, it has an easier
set-up process, faster turnaround time, and does not
require complex informatics for analysis. Also favorable
to laboratories with low test volume is the ability to test
one patient at a time without the need for batching.
However, the applicability of ddPCR is limited to known
variants and to those variants for which primers are
available. The former limitation makes it impossible to
identify other resistance mechanisms in patients progressing after ﬁrst-line TKI therapy. The latter makes it
difﬁcult to determine if sufﬁcient ctDNA was available
for testing, as the rare primary sensitizing variants
without available primers cannot be concurrently tested
as a marker for adequate tumor shedding. In addition,
multiplexing comes with challenges such as varying efﬁciency of individual assays, different primer annealing
temperatures,
possible
oligonucleotide
crossdimerization, and accurate separation of ﬂuorescent
signals from a limited number of reporter dyes with
overlapping emission spectra. However, it is possible to
develop discriminatory multiplex ddPCR assays that
enable very rapid and cost-effective monitoring for a
limited number of variants in serial plasma samples,
especially after target variants are identiﬁed using
broader sequence proﬁling of tumor tissue or a baseline
ctDNA sample.

Table 5. Phase 2 Concordance Rate of Local Testing Laboratory With Reference Laboratory
Local Laboratory #

# Cases

# Concordant Cases

% Concordance

Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Laboratory
Total

52
10
35
8
12
7
16
140

52
10
35
8
11
6
15
137

100.0
100.0
100.0
100.0
91.7
85.7
93.8
97.9

#

1
2
3
4
5
6
7

(ddPCR)
(NGS – Oncomine Lung cfDNA)
(NGS – Illumina TST15)
(Cobas)
(Entrogen)
(Entrogen)
(Cobas)

, number; cfDNA, cell-free DNA; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; TST15, TruSight Tumor 15.
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Table 6. Phase 2 Concordance Rate (With Reference
Laboratory) by Platform
Platform

# Cases

# Concordant
Results

% Concordance

ddPCR
NGS
Cobas (qPCR)
Entrogen (qPCR)

52
45
24
19

52
45
23
17

100.0
100.0
95.8
89.5

#

, number; ddPCR, droplet digital polymerase chain reaction; NGS, nextgeneration sequencing; qPCR, quantitative polymerase chain reaction.

More traditional PCR-based assays (Roche Cobas and
Entrogen ctEGFR kit) revealed a robust performance
during the analytical validation, though concordance
with the reference center was lower compared with the
NGS and ddPCR platforms. Both platforms missed
detecting the T790M variant in one patient. In each case,
the variant was identiﬁed by the reference laboratory. In
addition, laboratory 5, which used the Entrogen kit, also
detected the T790M in the plasma of a patient in which
the variant was not identiﬁed by the reference laboratory. It was not possible to establish whether these cases
represented false-positive or false-negative results
owing to the limited samples available. Regardless, the
high concordance rate reported in our study is in line
with previous studies.10,22,23
It was also noted that the overall positivity rate
observed for laboratory 7 (Cobas) was lower compared
with other participating labs, and the one positive case
identiﬁed by the reference laboratory was not identiﬁed
by laboratory 7. In addition, several samples from this
laboratory that were tested by the reference laboratory
were reported as inconclusive owing to failure to detect
ctDNA, which was determined by evaluating for the
sensitizing EGFR mutation as a proxy. Some of the factors, which could result in low ctDNA yield include
improper blood collection, prolonged storage of the
Streck tubes at less than ambient temperatures, insufﬁcient training/unfamiliarity with the assay, and recruitment of patients very early during disease progression
when ctDNA levels were lower than the assay LOD.
Because of the limited number of specimens tested, it
was not possible to identify the source of the
discrepancy.

Clinical Utility of Liquid Biopsy to Detect the
EGFR-T790M Resistance Mutation
EGFR-T790M detection in the plasma varied between
6.3 % and 37.5 % (average of 22.9 %) of all samples
(Table 4), consistent with the literature.9 The variable
detection rates may be owing to the low patient numbers
at some centers, and the variable clinical progression
patterns after ﬁrst or second-generation TKIs. For
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example, in some patients, acquired T790M variant
could be detected in ctDNA before radiological progression.24 Eligibility for this validation study required stage
IIIB or IV advanced EGFR-mutant NSCLC and along with
clinical signs of progression. However, no speciﬁc predetermined criteria were used to deﬁne clinical progression. In addition, because the presence of ctDNA has
been found to correlate with tumor burden, high metabolism, and the number and size of the metastatic lesions,25,26 and degree of vascular invasion27 variability
in these parameters would be expected to impact the
detection rate of ctDNA EGFR-T790M. This variability
may partly explain a proportion of patients in whom
neither the T790M nor sensitizing variants were detected in the plasma. Whereas these variants may have been
present at below the lower LOD (i.e., <0.5 %) in some
patients, it is also likely that some had tumors that were
ctDNA nonshedders. Of note, in a small number of patients from laboratory 1, second and third liquid biopsies
were tested after inconclusive results with the initial
blood draw and when patients could not undergo subsequent tissue biopsies. Of these patients, 23.1 % had a
positive T790M result with the subsequent draws.
Although these results were obtained in a limited number of patients from one laboratory, the ﬁndings reveal
the dynamic process of ctDNA tumor shedding in the
blood and suggest that it may be prudent to retest patients in whom the activating EGFR variant was not
detected in the initial blood draw, and who are not
eligible for subsequent invasive tissue biopsies.
Altogether, 69 patients (63.9 %) underwent repeat
tumor biopsy after a negative or inconclusive result for
liquid biopsy testing. A total of 25 of these patients
(36.2 %) subsequently tested positive for T790M in their
tumor biopsy (Supplementary Table 1), which is in line
with the 50 % to 60 % rate reported in the literature.28,29 This highlights key considerations regarding
T790M variant testing in patients progressing on ﬁrstline EGFR TKIs. Because of limitations associated with
tumor heterogeneity and the invasive nature of tissue
biopsies, evidence-based best practice guidelines
recommend liquid biopsy testing ﬁrst to determine
T790M status.30 However, recent studies have uncovered a complex interplay that determines ctDNA release
kinetics involving not only apoptosis and necrosis but
also senescence.31 This may explain why ctDNA levels do
not always correlate strongly with tumor burden and
suggests that these factors should be considered when
analyzing ctDNA as a subset of patients with low ctDNA
shed may still be at risk of clinical progression. Therefore, a negative or inconclusive liquid biopsy test should
be followed by tumor testing when possible.
In conclusion, plasma ctDNA is found to be a viable
option for identifying patients who would beneﬁt from
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TKI therapy for resistance mutations. Limited ctDNA
yield and complex kinetics introduce a risk of falsenegative results, even with sensitive and well-validated
molecular detection methods. To that end, this project
allowed the participating centers to develop rigorous
validation protocols and data from a considerable number of clinical samples to submit as evidence to support
clinical reimbursement by provincial authorities.
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